OncoSec to Present Immunological Data at World Pharma Week 2019

On June 13, 2019 OncoSec Medical Incorporated (OncoSec) (NASDAQ:ONCS), a company developing late-stage intratumoral cancer immunotherapies, reported that Christopher G. Twitty, Ph.D., Chief Scientific Officer, will present compelling immunological data from multiple clinical trials using the Company’s novel biomarker technology at World Pharma Week (WPW) 2019 taking place June 17-20 in Boston (Press release, OncoSec Medical, JUN 13, 2019, View Source [SID1234537064]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Twitty’s presentation, titled "Reversing Resistance to Definitive Anti-PD-1 Failures with Intratumoral IL-12 and Pembrolizumab Combination Therapy," will focus on approaches to overcome immune resistance mechanisms in cancer, namely reinvigorating T cell exhaustion with DNA-based cytokines, chemokines and T cell engaging antibodies.

Specifically, Dr. Twitty’s presentation will highlight:

Immunological data from OncoSec’s biomarker program taken from the OMS-102, KEYNOTE-695 (metastatic melanoma), and KEYNOTE-890 (metastatic triple negative breast cancer) clinical studies;
Developments associated with OncoSec’s visceral lesion applicator (VLA) and its next-generation plasmids;
Therapeutic rationale for intratumoral delivery of IL-12 for treatment across multiple solid tumor types.
The presentation will be made during the Combinations Strategies and Clinical Trials in Immuno-Oncology track, which is part of Cambridge Healthtech Institute’s Third Annual Clinical Innovation for Combination Immunotherapy meeting. A link to the meeting’s agenda and speaker panel can be found here.

With more than 1,500 senior delegates and 130 exhibitors slated for this year’s conference, WPW attracts renowned experts across the global medical sciences community and is dedicated to all stages of pharmaceutical R&D, from discovery though preclinical development and translational research to clinical biomarkers.